drugset / Trial / NCT06431594

A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)

NCT06431594

Phase 1 Recruiting 675 enrolled GlaxoSmithKline
RandomizedSequentialOpen-labelTreatment

Summary

The goal of this study is to assess the safety and tolerability of Mocertatug Rezetecan . The study will also see how the levels of Mo-Rez change over time at different dose amount

Timeline

Start
2024-07-02
Primary completion
2027-09-22
Completion
2029-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Mocertatug rezetecan Unknown

Indications